Early assessment of lung cancer immunotherapy response via circulating tumor DNA

SB Goldberg, A Narayan, AJ Kole, RH Decker… - Clinical Cancer …, 2018 - AACR
Purpose: Decisions to continue or suspend therapy with immune checkpoint inhibitors are
commonly guided by tumor dynamics seen on serial imaging. However, immunotherapy …
被引用次数：376 相关文章

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA

SB Goldberg, A Narayan, AJ Kole… - … : an official journal …, 2018 - pubmed.ncbi.nlm.nih.gov
Purpose: Decisions to continue or suspend therapy with immune checkpoint inhibitors are
commonly guided by tumor dynamics seen on serial imaging. However, immunotherapy …

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA

SB Goldberg, A Narayan, AJ Kole, RH Decker… - Clinical Cancer …, 2018 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Purpose: Decisions to continue or suspend
therapy with immune checkpoint inhibitors are commonly guided by tumor dynamics seen …

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.

SB Goldberg, A Narayan, AJ Kole… - … Cancer Research: an …, 2018 - europepmc.org
Purpose: Decisions to continue or suspend therapy with immune checkpoint inhibitors are
commonly guided by tumor dynamics seen on serial imaging. However, immunotherapy …
[HTML] nih.gov

[HTML][HTML] Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA

SB Goldberg, A Narayan, AJ Kole… - … cancer research: an …, 2018 - ncbi.nlm.nih.gov
Purpose Decisions to continue or suspend therapy with immune checkpoint inhibitors are
commonly guided by tumor dynamics seen on serial imaging. However, immunotherapy …

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.

SB Goldberg, A Narayan, AJ Kole… - … Cancer Research: an …, 2018 - europepmc.org
Purpose: Decisions to continue or suspend therapy with immune checkpoint inhibitors are
commonly guided by tumor dynamics seen on serial imaging. However, immunotherapy …